Imagine a crowd of over 500 applauding, giving you their utmost respect the moment you step on a stage. You are presented with a prestigious award sought after by many budding pharmacists. However, not everyone knows the sheer grit and determination that ultimately led to the success.
Kuala Lumpur APRIL 30, 2018 – Handicraft made with love by children with autism will be showcased throughout Malaysia, thanks to Champs, Malaysia’s largest vitamin brand for children which is collaborating with the National Autism Society of Malaysia (NASOM) to create greater awareness and acceptance of autism, besides enabling the latter’s products to be appreciated by a wider market.
Kuala Lumpur April 25, 2018 – CCM Duopharma Biotech Berhad (CCM Duopharma) has raised RM5,000 in funds, through its “Wear Green for Charity” campaign, for the MAA Medicare Charitable Foundation which offers subsidised dialysis treatment to needy patients who are suffering from chronic kidney disease.
Bangi APRIL 3, 2018 – CCM Duopharma Biotech Berhad (Duopharma) expects its newly completed Effervescent plant in Bangi, the country’s first ever such facility, to put the Company at the forefront of technology development in manufacturing high-quality pharmaceutical products using Effervescent technology that offers advantages over conventional manufacturing of healthcare products.
Kuala Lumpur – Popularity of CCM Duopharma Biotech Berhad (Duopharma) sponsored drama series titled ‘Lafazkan Kalimah Cintamu’ has boosted sales of Flavettes Effervescent significantly due to the drama’s high rating and trending on the social media recently.
Bangi, Selangor – CCM Duopharma Biotech Berhad’s (Duopharma) effort in intensifying its Halal integrity in the Halal pharmaceutical sector was further endorsed via the visit of Datuk Dr. Zulkifli Bin Mohamad Al-Bakri, Mufti of the Federal Territory, to its manufacturing plant located in Bangi recently.
Kuala Lumpur, February 27 2018 – CCM Duopharma Biotech Berhad (Duopharma) has proposed a bonus issue of up to 371,945,333 new ordinary shares on the basis of four (04) bonus shares for every three (03) existing shares, reflecting the company’s stronger fundamentals after it completed its demerger exercise earlier this year. Its Group Managing Director, Leonard Ariff Abdul Shatar said the bonus issue is aimed at rewarding existing shareholders for their loyalty and continuous support as well as increasing the share capital of the company to a level that will better reflect the current scale of operations and assets employed by Duopharma and its subsidiaries. In the statement to the local bourse today, Duopharma also announced that it is declaring its final dividend of six (06) sen per share and the Company is proposing to undertake the Proposed Dividend Reinvestment Plan (DRP), whereby the shareholders will be given the option to elect to reinvest the whole or part of the dividend into new ordinary shares of Duopharma.
Kuala Lumpur, February 27 2018 – CCM Duopharma Biotech Berhad (Duopharma) has proposed a bonus issue of up to 371,945,333 new ordinary shares on the basis of four (04) bonus shares for every three (03) existing shares, reflecting the company’s stronger fundamentals after it completed its demerger exercise earlier this year.
Kuala Lumpur – CCM Duopharma Biotech Berhad (CCMD) has entered into a collaboration with Natco Pharma Ltd of India to commercialise a range of Hepatitis C products in Malaysia to improve access and affordability for patients who currently have to fork out large sums of money for treatment in the country.
Kuala Lumpur – Once considered rare, autism is now on the rise and approximately 67 million worldwide live with autism. According to the Malaysian Department of Social Welfare, there are close to 13,000 individuals in Malaysia who are registered as autistic in 2014. Meanwhile, the Malaysian Ministry of Health reported that autism cases in the country are on the rise every year, emphasising the importance of early treatment to improve a child’s development.
Kuala Lumpur – Many champions among us often go unnoticed because their gifts and talents come in different forms that we fail to recognise. Children with autism are the unsung heroes, who are more often misunderstood than celebrated.
New Delhi, India – Malaysia’s largest generic pharmaceutical manufacturer, CCM Duopharma Biotech Berhad (CCMD), a subsidiary of Chemical Company of Malaysia Berhad (CCM) has entered into a strategic alliance with India’s Natco Pharma Limited (Natco) and Biocon Limited (Biocon) to offer affordable cancer and insulin therapies in Malaysia.
Kuala Lumpur – CCM Duopharma Biotech Berhad (CCMD), Malaysia’s largest pharmaceutical manufacturer registered a 16 per cent increase in revenue to RM312.94 million for the financialyear ended 31 December 2016 (FY 2016) from RM269.79 million in the previous year.
Kuala Lumpur – CCM Pharmaceuticals Sdn Bhd (CCMP), a subsidiary of CCM Duopharma Biotech Berhad (CCMD), and Biocon Sdn Bhd (a subsidiary of Biocon Ltd) have been awarded a Letter of Award (LOA) by the Ministry of Health (MOH) to supply Human Insulin to all government hospitals and clinics valued at RM300 million for three years until December 1, 2019.
Duopharma Biotech Berhad recorded cumulative revenue of RM482.24 million for the first half of FY2026 ended 30 June 2026, which saw the Group’s Profit Before Tax growing 32.1% year-on-year to RM79.71 million, while Profit After Tax rose 32.2% to RM60.59 million, compared to the corresponding period in the preceding year.
Duopharma Biotech Berhad officially launched the Flavettes Merdeka 2026 campaign today, themed ‘Flavettes Setia Menemani Setiap Generasi’ and featuring a multi-prong collaboration with Tourism Malaysia, Watsons Malaysia and Kapten Batik.
Biocon Limited, an innovation-led global biopharmaceutical company, announced that its long-standing partner, Duopharma Biotech Berhad via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health, Malaysia, valued at over MYR 225 million this year.
Duopharma Biotech Berhad held its 25th Annual General Meeting today, capping a successful FY2025 ended 31 December 2025, that saw the Company growing its revenue by 14.5% to RM931.69 million, from RM813.70 million in FY2024.
Duopharma Biotech Berhad recorded resilient financial performance in the first quarter ended 31 March 2026, delivering a stronger Profit Before Tax (“PBT”) of RM 40.41 million, and Profit After Tax (“PAT”) of RM30.71 million, increasing 19.8% year-on-year, despite Q1FY2026 revenue of RM247.88 million dropping 5.7% compared to RM262.74 million in the same period last year.
Duopharma Biotech Berhad reported a revenue of RM931.69 million for the year ended 31 December 2025, up 14.5% compared to revenue of RM813.70 million in financial year 2024.